Hikma Pharmaceuticals has launched the first-of-its-kind, ready-to-use vancomycin premix with room-temperature stability under the brand name TYZAVAN (vancomycin injection, USP).

"The approval of TYZAVAN underscores our team's exceptional R&D capabilities in developing innovative healthcare solutions that enhance patient care, particularly in time-sensitive situations. TYZAVAN, available in ready-to-use aseptically filled bags, exemplifies our commitment to rethinking essential medicines by making them faster to administer, easier to manage and available when patients need them the most. Our talented and knowledgeable commercial team will drive the launch of TYZAVAN, ensuring its successful introduction and adoption in US hospitals," said Jon Kafer, Vice President—Commercial, Hikma Injectables.

TYZAVAN is offered in pre-filled ready-to-use bags that will help hospitals, pharmacists, doctors and nurses treat patients faster, more easily, and with reduced risk. It is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients for whom appropriate dosing with this formulation can be achieved: septicemia, infective endocarditis, skin and skin structure infections, bone infections and lower respiratory tract infections.

The name TYZAVAN stands for "time-saving vancomycin," reflecting its ready-to-use dosage form and its purpose: delivering timely, simplified treatment when every minute counts. TYZAVAN is the only FDA-approved vancomycin injection available for adults and paediatric patients that can be stored at room temperature and used immediately eliminating the need for compounding, thawing, assembly or activation to streamline preparation and accelerate treatment.